Administration of RLYB211 and RLYB212 to expectant at-risk mothers is designed to rapidly eliminate fetal HPA-1a positive platelets from a mother’s circulation and prevent maternal ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--#Rallybio--Rallybio, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients ...